Jun 18, 2020
Worldwide Human Papillomavirus (HPV) Vaccines Overview 2020 - Pipeline & Marketed Vaccines, Regulatory Events, Clinical Trial Landscape, Future Trends, KOL Insights, Unmet Needs, Sales (2015-2024)
Jun 18, 2020
Neauvia North America continues its commitment to Safety and Innovation in Aesthetics
Jun 17, 2020
ISA Pharmaceuticals Strengthens Strategic Immuno-Oncology Collaboration With Regeneron
Jun 16, 2020
U.S. Genital Warts Market Analysis, 2017-2030 - Epidemiology, Drugs, Therapies, Vaccines, Companies, Unmet Needs, Reimbursement
Jun 16, 2020
Support for cervical cancer screening using Pap and HPV testing together continues to grow among health care providers and women
May 12, 2020
INOVIO to Present at RBC Capital Markets Virtual Global Healthcare Conference
May 11, 2020
INOVIO Reports First Quarter 2020 Financial Results; Provides Business Update
Apr 20, 2020
Precigen Announces Clearance of IND to Initiate Phase I/II Study for First-in-Class PRGN-2009 AdenoVerse(TM) Immunotherapy to Treat HPV-positive (HPV+) Solid Tumors
Apr 15, 2020
INOVIO to Host its Annual Meeting of Stockholders in Virtual Format and at a New Time
Mar 30, 2020
INOVIO Interim Results of an Open-Label Phase 2 Trial of VGX-3100 Show Efficacy Against HPV-associated Vulvar Dysplasia
Mar 19, 2020
ISA Pharma Publishes Phase 2 Study Data in Major Peer-reviewed Journal
Mar 12, 2020
INOVIO Pharmaceuticals Reports 2019 Fourth Quarter and Year-End Financial Results
Mar 02, 2020
Inovio Pharmaceuticals to Report Fourth Quarter and Full Year 2019 Financial Results on March 12, 2020
Mar 02, 2020
Inovio Pharmaceuticals to Report Fourth Quarter and Full Year 2019 Financial Results on March 12, 2020
Feb 14, 2020
The global HPV testing market is expected to grow at a CAGR of over 12% during the period 2019-2025
Feb 13, 2020
2020-2025 Human Papillomavirus (HPV) Testing Industry Report - Roche, Qiagen, Hologic and Abbott are Dominating the Competition
Feb 12, 2020
The Global Human Papillomavirus (HPV) Testing Market to Reach Revenues of Over $1 Billion During the Period 2020 -2025 - Market Research by Arizton
Feb 10, 2020
Inovio Receives Authorization from the U.S. FDA To Begin Phase 1/2 Clinical Trial for INO-3107, a DNA Medicine To Treat a Rare Disease -- Recurrent Respiratory Papillomatosis (RRP)
Feb 07, 2020
Disease Analysis: Human Papillomavirus (HPV) Vaccines
Feb 03, 2020
Inovio Publishes Patient Benefit Results From A Pilot Clinical Study in Recurrent Respiratory Papillomatosis (RRP), A Rare Disease Caused by HPV Infections